人类多能干细胞源心肌细胞的研究进展与应用前景  

Current Progress and Potential Application for Human Pluripotent Stem Cells-derived Cardiomyocytes

作　　者：李晴[1] 刘靖[1] 徐秀琴[1] 

机构地区：[1]厦门大学医学院基础医学部厦门大学医学院干细胞与再生医学研究所干细胞与心脏再生实验室,厦门361102

出　　处：《中国细胞生物学学报》2013年第3期251-261,共11页Chinese Journal of Cell Biology

基　　金：国家自然科学基金(批准号:81270199;81201275);国家高技术研究发展计划(863)(批准号:2011AA020101);中央高校基本科研业务费专项资金(批准号:2010121107)资助的课题~~

摘　　要：人类多能干细胞(human pluripotent stem cells,hPSC)具有无限增殖的能力并可体外分化成心肌细胞,可作为新型的细胞源用于心脏疾病的细胞替代疗法、药物检测及心脏发育生物学的基础研究。hPSC包括人胚胎干细胞(human embryonic stem cells,hESC)和诱导型人多能干细胞(human induced pluripotent stem cells,hiPSC),后者的出现不仅使干细胞个性化治疗成为可能,同时规避了人胚胎干细胞应用的医学伦理问题,具有较大的发展空间。尽管hPSC源心肌细胞的应用研究已取得极大进展,但将这种心肌细胞应用于临床仍有许多技术问题需要解决。该文将综述hPSC源心肌细胞的技术进展,探讨hPSC源心肌细胞的应用前景,并对存在的问题和挑战也进行了讨论。Human pluripotent stem cells （hPSC） with the ability to differentiate into cardiomyocytes in culture, open the possibility of generating a virtually unlimited supply of cardiomyocytes for clinical applications, drug discovery, and provide an in vitro model for heart development. The past decade sees significant progress in this field. The advert of induced pluripotent stem cell （iPSC） technology enables personalized cell therapies and negates ethical concerns surrounding human embryonic stem cells. Despite the great progress, the clinical use of hPSC-cardiomyocytes as regenerative medicine is still in its infancy, and many technical hurdles remain to be ad- dressed. This review summarizes technical advances toward the generation of clinically relevant human cardiomyo- cytes from hPSC, including the methods of differentiation, enrichment, and scale-up. We also provide an update on the potential of hPSC-cardiomyocytes to be used as a reagent for clinical application, pharmaceutical drug develop- ment, and basic cardiovascular research. Furthermore, we highlight the key barriers that need to overcome before hPSC-mediated human heart repair becomes a reality.

关 键 词：胚胎干细胞 心肌分化 再生 药物筛选 

分 类 号：R329[医药卫生—人体解剖和组织胚胎学]